David Scheinberg
Chairman, Experimental Therapeutics Center · New York Presbyterian Hospital
Credentials: · · ·
History
PresentExperimental Therapeutics Center · New York Presbyterian Hospital
- Present
Molecular Pharmacology Program Department · New York Presbyterian Hospital
- Present
Center for Experimental Therapeutics · New York Presbyterian Hospital
- 1983–1986
- 1979–1983
Research
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
New England Journal of Medicine · 1991 · 1,289 citations
Blood · 2011 · 1,083 citations
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
New England Journal of Medicine · 1998 · 1,039 citations
32 papers
- PM
23 papers
- SL
22 papers
- AH
16 papers
- PC
15 papers · 3 as a fellow
14 papers
11 papers · 3 as a resident
- CD
11 papers
Grants
- 2020–2027
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.
National Cancer Institute · R35
Contact PI · $7.2M · Sloan-Kettering Inst Can Research
- 1997–2025
Immunobiology of Allogeneic Hematopoietic Cell Transplantation
National Cancer Institute · P01
Contact PI · $8.9M · Sloan-Kettering Inst Can Research
- 1991–2020
Improving Specificity of Therapeutic Antibodies for Cancer.
National Cancer Institute · R01
Contact PI · $8.5M · Sloan-Kettering Inst Can Research
- 1982–2011
Targeted Antigen Receptor Treatment of Cancer
National Cancer Institute · P01
Contact PI · $6.3M · Sloan-Kettering Inst Can Research
Clinical trials
- 2000–2004
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
Study chair · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
- 1994–2003
Study chair · Completed · Phase 2
Memorial Sloan Kettering Cancer Center